Zoetis (NYSE: ZTS), the world’s largest animal health company, is scheduled to report second-quarter 2026 results on Thursday, August 6, before the market opens. Analysts expect revenue of approximately $2.49–2.51 billion and adjusted EPS of $1.81–1.86, reflecting modest year-over-year growth against a challenging first quarter.
The report is a critical test for the companion animal pharmaceutical market. In Q1 2026, Zoetis missed both revenue and EPS estimates and lowered full-year guidance, citing increased price sensitivity among pet owners and declining veterinary visits. U.S. companion animal product sales fell 11% in Q1, sending the stock to sharp declines. Full-year 2026 guidance now calls for revenue of $9.68–9.96 billion and adjusted EPS of $6.85–7.00.
Investors will focus on whether U.S. vet clinic traffic and parasiticide demand have stabilized, as well as performance in dermatology, osteoarthritis pain, and diagnostics. International and livestock segments have shown resilience and may offset continued domestic softness. Beyond Zoetis, the commentary will set the tone for veterinary services, pet insurance, and retail veterinary networks in the second half of 2026.
